Treating COPD in older and oldest old patients

Andrea Corsonello, Simone Scarlata, Claudio Pedone, Silvia Bustacchini, Sergio Fusco, Anna Zito, Raffaele Antonelli Incalzi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The treatment of older and oldest old patients with COPD poses several problems and should be tailored to specific outcomes, such as physical functioning. Indeed, impaired homeostatic mechanisms, deteriorated physiological systems, and limited functional reserve mainly contribute to this complex scenario. Therefore, we reviewed the main difficulties in managing therapy for these patients and possible remedies. Inhaled long acting beta-agonists (LABA) and anticholinergics (LAMA) are the mainstay of therapy in stable COPD, but it should be considered that pharmacological response and safety profile may vary significantly in older patients with multimorbidity. Their association with inhaled corticosteroids is recommended only for patients with severe or very severe air-flow limitation or with frequent exacerbations despite bronchodilator treatment. In hypoxemic patients, long-term oxygen therapy (LTOT) may improve not only general comfort and exercise tolerance, but also cognitive functions and sleep. Non-pharmacological interventions, including education, physical exercise, nutritional support, pulmonary rehabilitation and telemonitoring can importantly contribute to improve outcomes. Older patients with COPD should be systematically evaluated for the presence of risk factors for non-adherence, and the inhaler device should be chosen very carefully. Comorbidities, such as cardiovascular diseases, chronic kidney disease, osteoporosis, obesity, cognitive, visual and auditory impairment, may significantly affect treatment choices and should be scrutinized. Palliative care is of paramount importance in end-stage COPD. Finally, treatment of COPD exacerbations has been also reviewed. Therapeutic decisions should be founded on a careful assessment of cognitive and functional status, comorbidity, polypharmacy, and age-related changes in pharmacokinetics and pharmacodynamics in order to minimize adverse drug events, drug-drug or drug-disease interactions, and non-adherence to treatment.

Original languageEnglish
Pages (from-to)1672-1689
Number of pages18
JournalCurrent Pharmaceutical Design
Volume21
Issue number13
Publication statusPublished - 2015

Fingerprint

Chronic Obstructive Pulmonary Disease
Comorbidity
Therapeutics
Polypharmacy
Exercise Tolerance
Nutritional Support
Nebulizers and Vaporizers
Bronchodilator Agents
Vision Disorders
Cholinergic Antagonists
Drug-Related Side Effects and Adverse Reactions
Chronic Renal Insufficiency
Palliative Care
Drug Interactions
Pharmaceutical Preparations
Cognition
Osteoporosis
Adrenal Cortex Hormones
Sleep
Cardiovascular Diseases

Keywords

  • Adherence
  • Chronic obstructive pulmonary disease (COPD)
  • Comorbidity
  • Long-acting antichilinergics (LAMA)
  • Long-acting beta agonists (LABA)
  • Older

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Medicine(all)

Cite this

Corsonello, A., Scarlata, S., Pedone, C., Bustacchini, S., Fusco, S., Zito, A., & Incalzi, R. A. (2015). Treating COPD in older and oldest old patients. Current Pharmaceutical Design, 21(13), 1672-1689.

Treating COPD in older and oldest old patients. / Corsonello, Andrea; Scarlata, Simone; Pedone, Claudio; Bustacchini, Silvia; Fusco, Sergio; Zito, Anna; Incalzi, Raffaele Antonelli.

In: Current Pharmaceutical Design, Vol. 21, No. 13, 2015, p. 1672-1689.

Research output: Contribution to journalArticle

Corsonello, A, Scarlata, S, Pedone, C, Bustacchini, S, Fusco, S, Zito, A & Incalzi, RA 2015, 'Treating COPD in older and oldest old patients', Current Pharmaceutical Design, vol. 21, no. 13, pp. 1672-1689.
Corsonello A, Scarlata S, Pedone C, Bustacchini S, Fusco S, Zito A et al. Treating COPD in older and oldest old patients. Current Pharmaceutical Design. 2015;21(13):1672-1689.
Corsonello, Andrea ; Scarlata, Simone ; Pedone, Claudio ; Bustacchini, Silvia ; Fusco, Sergio ; Zito, Anna ; Incalzi, Raffaele Antonelli. / Treating COPD in older and oldest old patients. In: Current Pharmaceutical Design. 2015 ; Vol. 21, No. 13. pp. 1672-1689.
@article{ce7dfd5bd0184e1ebdbd1c2721d61d70,
title = "Treating COPD in older and oldest old patients",
abstract = "The treatment of older and oldest old patients with COPD poses several problems and should be tailored to specific outcomes, such as physical functioning. Indeed, impaired homeostatic mechanisms, deteriorated physiological systems, and limited functional reserve mainly contribute to this complex scenario. Therefore, we reviewed the main difficulties in managing therapy for these patients and possible remedies. Inhaled long acting beta-agonists (LABA) and anticholinergics (LAMA) are the mainstay of therapy in stable COPD, but it should be considered that pharmacological response and safety profile may vary significantly in older patients with multimorbidity. Their association with inhaled corticosteroids is recommended only for patients with severe or very severe air-flow limitation or with frequent exacerbations despite bronchodilator treatment. In hypoxemic patients, long-term oxygen therapy (LTOT) may improve not only general comfort and exercise tolerance, but also cognitive functions and sleep. Non-pharmacological interventions, including education, physical exercise, nutritional support, pulmonary rehabilitation and telemonitoring can importantly contribute to improve outcomes. Older patients with COPD should be systematically evaluated for the presence of risk factors for non-adherence, and the inhaler device should be chosen very carefully. Comorbidities, such as cardiovascular diseases, chronic kidney disease, osteoporosis, obesity, cognitive, visual and auditory impairment, may significantly affect treatment choices and should be scrutinized. Palliative care is of paramount importance in end-stage COPD. Finally, treatment of COPD exacerbations has been also reviewed. Therapeutic decisions should be founded on a careful assessment of cognitive and functional status, comorbidity, polypharmacy, and age-related changes in pharmacokinetics and pharmacodynamics in order to minimize adverse drug events, drug-drug or drug-disease interactions, and non-adherence to treatment.",
keywords = "Adherence, Chronic obstructive pulmonary disease (COPD), Comorbidity, Long-acting antichilinergics (LAMA), Long-acting beta agonists (LABA), Older",
author = "Andrea Corsonello and Simone Scarlata and Claudio Pedone and Silvia Bustacchini and Sergio Fusco and Anna Zito and Incalzi, {Raffaele Antonelli}",
year = "2015",
language = "English",
volume = "21",
pages = "1672--1689",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "13",

}

TY - JOUR

T1 - Treating COPD in older and oldest old patients

AU - Corsonello, Andrea

AU - Scarlata, Simone

AU - Pedone, Claudio

AU - Bustacchini, Silvia

AU - Fusco, Sergio

AU - Zito, Anna

AU - Incalzi, Raffaele Antonelli

PY - 2015

Y1 - 2015

N2 - The treatment of older and oldest old patients with COPD poses several problems and should be tailored to specific outcomes, such as physical functioning. Indeed, impaired homeostatic mechanisms, deteriorated physiological systems, and limited functional reserve mainly contribute to this complex scenario. Therefore, we reviewed the main difficulties in managing therapy for these patients and possible remedies. Inhaled long acting beta-agonists (LABA) and anticholinergics (LAMA) are the mainstay of therapy in stable COPD, but it should be considered that pharmacological response and safety profile may vary significantly in older patients with multimorbidity. Their association with inhaled corticosteroids is recommended only for patients with severe or very severe air-flow limitation or with frequent exacerbations despite bronchodilator treatment. In hypoxemic patients, long-term oxygen therapy (LTOT) may improve not only general comfort and exercise tolerance, but also cognitive functions and sleep. Non-pharmacological interventions, including education, physical exercise, nutritional support, pulmonary rehabilitation and telemonitoring can importantly contribute to improve outcomes. Older patients with COPD should be systematically evaluated for the presence of risk factors for non-adherence, and the inhaler device should be chosen very carefully. Comorbidities, such as cardiovascular diseases, chronic kidney disease, osteoporosis, obesity, cognitive, visual and auditory impairment, may significantly affect treatment choices and should be scrutinized. Palliative care is of paramount importance in end-stage COPD. Finally, treatment of COPD exacerbations has been also reviewed. Therapeutic decisions should be founded on a careful assessment of cognitive and functional status, comorbidity, polypharmacy, and age-related changes in pharmacokinetics and pharmacodynamics in order to minimize adverse drug events, drug-drug or drug-disease interactions, and non-adherence to treatment.

AB - The treatment of older and oldest old patients with COPD poses several problems and should be tailored to specific outcomes, such as physical functioning. Indeed, impaired homeostatic mechanisms, deteriorated physiological systems, and limited functional reserve mainly contribute to this complex scenario. Therefore, we reviewed the main difficulties in managing therapy for these patients and possible remedies. Inhaled long acting beta-agonists (LABA) and anticholinergics (LAMA) are the mainstay of therapy in stable COPD, but it should be considered that pharmacological response and safety profile may vary significantly in older patients with multimorbidity. Their association with inhaled corticosteroids is recommended only for patients with severe or very severe air-flow limitation or with frequent exacerbations despite bronchodilator treatment. In hypoxemic patients, long-term oxygen therapy (LTOT) may improve not only general comfort and exercise tolerance, but also cognitive functions and sleep. Non-pharmacological interventions, including education, physical exercise, nutritional support, pulmonary rehabilitation and telemonitoring can importantly contribute to improve outcomes. Older patients with COPD should be systematically evaluated for the presence of risk factors for non-adherence, and the inhaler device should be chosen very carefully. Comorbidities, such as cardiovascular diseases, chronic kidney disease, osteoporosis, obesity, cognitive, visual and auditory impairment, may significantly affect treatment choices and should be scrutinized. Palliative care is of paramount importance in end-stage COPD. Finally, treatment of COPD exacerbations has been also reviewed. Therapeutic decisions should be founded on a careful assessment of cognitive and functional status, comorbidity, polypharmacy, and age-related changes in pharmacokinetics and pharmacodynamics in order to minimize adverse drug events, drug-drug or drug-disease interactions, and non-adherence to treatment.

KW - Adherence

KW - Chronic obstructive pulmonary disease (COPD)

KW - Comorbidity

KW - Long-acting antichilinergics (LAMA)

KW - Long-acting beta agonists (LABA)

KW - Older

UR - http://www.scopus.com/inward/record.url?scp=84930918247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930918247&partnerID=8YFLogxK

M3 - Article

C2 - 25633118

AN - SCOPUS:84930918247

VL - 21

SP - 1672

EP - 1689

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 13

ER -